Alibaba Health Information Technology Ltd (HKG: 0241), the health industry arm of Chinese e-commerce giant Alibaba Group, has announced strategic collaboration agreements with a consortium of pharmaceutical companies. The collaborations include US-based Viatris (NASDAQ: VTRS) and Chinese firms Qilu Pharmaceutical, Chongqing Taiji Industry (Group) Co., Ltd (SHA: 600129), Shandong Dyne Marine Biopharmaceutical Co., Ltd., and Jiangzhong Group (SHA: 600750). These partnerships will focus on expanding digital health services across online retail, category expansion, new drug launches, and disease education, with no financial details disclosed.
The partnership with Viatris, specializing in cardiovascular diseases, is designed to enhance the reach of originator brand medicines in the ex-hospital setting and establish a patient management platform. Qilu Pharmaceutical will utilize its extensive product pipeline and Alibaba Health’s vast user base and channel capabilities to efficiently cover its volume-based procurement drugs in the ex-hospital setting. Taiji Industry is set to elevate its products to a top Chinese patent drug brand through this collaboration. Dyne Marine Bio and Alibaba Health will establish an online “service center” in pediatrics, offering specialized online pharmaceutical services and personalized consultation and treatment plans for maternal and child health and chronic disease management. Jiangzhong Group and Alibaba Health will work together to leverage digital capabilities, pinpoint user pain points, meet consumer health needs more effectively, and create a personalized digital marketing system through content education and in-depth exploration of brand product attributes combined with the purchasing market. – Flcube.com
